New JP Ultraviolet-Visible and Infrared Reference Spectra Published
In March 2023, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published the "JP Drafts (March 2023) No.2". In this context, five new Ultraviolet-visible and Infrared reference spectra were published.
The following spectra were made available as PDF files:
- Aripiprazole
- Febuxostat
- Lornoxicam
- Oxaliplatin
- Tolvaptan
New monographs of these and for a few other APIs and tablets have also been published.
The comment period runs from 01 March to 31 May 2023. To submit remarks, a form for comments has to be downloaded and sent by e-mail to the authority after it has been filled in.
Related GMP News
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation
21.05.2026LCGC Article on Analytical Procedure Lifecycle Approaches



